In 1961,methicillin–resistant Staphylococcus aureus (MRSA) was first detected in United Kingdom, since then MRSA rapidly spread worldwide and drew much concern because it gives rise to serious problems in either hospital settings or community. Creeping minimum inhibitory concentration (MIC) of Vancomycin in MRSA isolates have raised doubts on the rationale of using it for treatment. Treatment failure is associated with an increase in the MIC as well as a decrease in the rate of bacterial killing. Linezolid is the only antibiotic with good activity against MRSA available as an oral formulation; making it desirable for outpatient treatment. It is safe and effective for use in children and newborns as well as adults.